- Home
- GOVX vs CTXR Comparison
GOVX vs CTXR Comparison
Compare GOVX & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- CTXR
- Stock Information
- Founded
- GOVX 2001
- CTXR 2007
- Country
- GOVX United States
- CTXR United States
- Employees
- GOVX N/A
- CTXR N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- CTXR Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- CTXR Health Care
- Exchange
- GOVX Nasdaq
- CTXR Nasdaq
- Market Cap
- GOVX 15.5M
- CTXR 14.6M
- IPO Year
- GOVX N/A
- CTXR N/A
- Fundamental
- Price
- GOVX $0.49
- CTXR $1.90
- Analyst Decision
- GOVX Strong Buy
- CTXR Strong Buy
- Analyst Count
- GOVX 5
- CTXR 3
- Target Price
- GOVX $12.40
- CTXR $53.00
- AVG Volume (30 Days)
- GOVX 2.4M
- CTXR 6.9M
- Earning Date
- GOVX 08-05-2025
- CTXR 08-11-2025
- Dividend Yield
- GOVX N/A
- CTXR N/A
- EPS Growth
- GOVX N/A
- CTXR N/A
- EPS
- GOVX N/A
- CTXR N/A
- Revenue
- GOVX $5,591,576.00
- CTXR N/A
- Revenue This Year
- GOVX N/A
- CTXR N/A
- Revenue Next Year
- GOVX N/A
- CTXR N/A
- P/E Ratio
- GOVX N/A
- CTXR N/A
- Revenue Growth
- GOVX N/A
- CTXR N/A
- 52 Week Low
- GOVX $0.43
- CTXR $0.65
- 52 Week High
- GOVX $11.18
- CTXR $26.25
- Technical
- Relative Strength Index (RSI)
- GOVX 29.07
- CTXR 75.41
- Support Level
- GOVX $0.85
- CTXR $0.76
- Resistance Level
- GOVX $0.98
- CTXR $1.45
- Average True Range (ATR)
- GOVX 0.15
- CTXR 0.24
- MACD
- GOVX -0.04
- CTXR 0.09
- Stochastic Oscillator
- GOVX 5.54
- CTXR 100.00
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.